AMERICAN JOURNAL OF OPHTHALMOLOGY, vol.144, no.1, pp.124-126, 2007 (SCI-Expanded)
PURPOSE: To report the visual acuity (VA) and foveal thickness (FT) changes after intravitreal bevacizumab for diabetic macular edema (DME) in previously vitrectomized eyes.